New York State Common Retirement Fund Has $14.28 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

New York State Common Retirement Fund lowered its position in BioNTech SE (NASDAQ:BNTX) by 42.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 125,296 shares of the company’s stock after selling 92,771 shares during the quarter. New York State Common Retirement Fund owned 0.05% of BioNTech worth $14,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC acquired a new position in shares of BioNTech in the third quarter worth approximately $59,485,000. Braidwell LP bought a new stake in BioNTech in the third quarter valued at approximately $29,425,000. abrdn plc boosted its holdings in BioNTech by 334.4% in the third quarter. abrdn plc now owns 225,992 shares of the company’s stock valued at $26,841,000 after acquiring an additional 173,969 shares during the last quarter. Finally, Redmile Group LLC acquired a new stake in BioNTech during the 3rd quarter valued at approximately $18,345,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ BNTX opened at $120.01 on Monday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $117.26 and a 200 day simple moving average of $111.03. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a market cap of $28.77 billion, a P/E ratio of -57.15 and a beta of 0.17.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BNTX. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Berenberg Bank began coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Truist Financial initiated coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.